Manhattan, New York (PressExposure) February 19, 2011 -- With age, our body produces more harmful free radicals and less natural antioxidants to defend against them. It's this excessive free radical damage - known as oxidation - and its sister process known as glycosylation- which can cause chronic tissue damage and lead to cataracts. Can-C is a remarkable eye-drop that contains a natural di-peptide known as N-acetylcarnosine, and Can-C are the only eye-drops proven to help arrest and even reverse senile cataracts without surgery. Can-C is a non-invasive, anti-oxidant, anti-glycation eye-drop that has been approved and patented by the Russian research group- Innovative Vision Products, who developed the technology behind this breakthrough in cataract treatment.
Can-C is an important discovery because, for the first time ever, it offers an effective alternative to cataract extraction. Can-C taken on a regular basis has been shown to have a demonstrable affect on cataracts within one month of use. This is because Can-C not only protects the eye tissues from harmful free radicals, it also reverses existing damage. Can-C eye-drops allow the patient to keep their natural lens rather than cope with an artificial one.
The statistics in the human trials show that Can-C eye-drops applied for 6-months twice daily into the eye, in patients all suffering from senile cataract had the following results: 88.9% had an improvement of glare sensitivity, 41.5% had an improvement of the transmissivity of the lens and 90% had an improvement in visual acuity.
These results have also been described in Dr. Marios Kyriazis book called 'the cataract cure' and available through Amazon.
International Ant aging Systems (IAS) has dedicated itself to supplying the very latest commercially available products, giving you direct access to many different types of "hard to obtain" substances. At the same time they demand that everything they offer meets the highest possible pharmaceutical standards. After all it is through quality that they ensure efficacy. For further reading sections please visit.